New hope for immunotherapy side effects: which drug works best?
NCT ID NCT04407247
First seen Jan 05, 2026 · Last updated Apr 30, 2026 · Updated 16 times
Summary
This study compares two medications, infliximab and vedolizumab, to treat colitis (colon inflammation) caused by immune checkpoint inhibitor therapy in cancer patients. About 47 adults with genitourinary cancer, melanoma, or non-small cell lung cancer are participating. The goal is to find which drug, combined with steroids, better controls the colitis and reduces side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LUNG NON-SMALL CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.